STOCK TITAN

I-MAB Filed 2023 Annual Report on Form 20-F

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

I-Mab, a global biotech company, filed its 2023 annual report on Form 20-F with the SEC. The report focuses on the development of immunotherapies for cancer treatment. It can be accessed on the company's investor relations website and the SEC's website. Shareholders and ADS holders can request hard copies free of charge.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction 1 Alert

-1.67% News Effect

On the day this news was published, IMAB declined 1.67%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

ROCKVILLE, Md., April 30, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that it has filed its annual report on Form 20-F for the year ended December 31, 2023 with the U.S. Securities and Exchange Commission ("SEC") on April 30, 2024.

The annual report is available on the Company's investor relations website at ir.i-mabbiopharma.com and on the SEC's website at www.sec.gov. The Company will provide hard copies of the annual report, free of charge, to its shareholders and ADS holders upon written request. Requests should be directed to Investor Relations, I-Mab, 2440 Research Blvd., Suite 400, Rockville, MD, 20850.

About I-Mab

I-Mab (NASDAQ: IMAB) is a U.S.-based global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in the U.S. in Rockville, Maryland, and in San Diego, California. For more information, please visit http://www.i-mabbiopharma.com and follow us on LinkedIn and X.

I-Mab Contacts

Investors & Media

Tyler Ehler

Senior Director, Investor Relations

IR@i-mabbiopharma.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-filed-2023-annual-report-on-form-20-f-302130508.html

SOURCE I-Mab Biopharma

FAQ

Where can I access I-Mab's 2023 annual report?

I-Mab's 2023 annual report on Form 20-F can be accessed on the company's investor relations website and the SEC's website.

What is I-Mab's stock symbol?

I-Mab's stock symbol is IMAB.

How can shareholders and ADS holders request a hard copy of the annual report?

Shareholders and ADS holders can request hard copies of the annual report free of charge by contacting Investor Relations at I-Mab's address in Rockville, MD.
I-Mab

NASDAQ:IMAB

IMAB Rankings

IMAB Latest News

IMAB Latest SEC Filings

IMAB Stock Data

533.68M
78.65M
21.43%
20%
2.43%
Biotechnology
Healthcare
Link
United States
Rockville